Fred Alger Management’s Axsome Therapeutics AXSM Stock Holding History

Fred Alger Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,373	Closed	-$860K	–	439
2025 Q1	$860K	Buy	+7,373	New	+$840K	﹤0.01%	335
2024 Q4	–	Sell	-9,466	Closed	-$851K	–	417
2024 Q3	$851K	Buy	+9,466	New	+$826K	﹤0.01%	354
2023 Q3	–	Sell	-17,422	Closed	-$1.25M	–	470
2023 Q2	$1.25M	Buy	+17,422	New	+$1.29M	0.01%	368
2021 Q1	–	Sell	-14,670	Closed	-$1.2M	–	483
2020 Q4	$1.2M	Sell	14,670 -331	-2%	-$24.8K	﹤0.01%	357
2020 Q3	$1.07M	Sell	15,001 -7,999	-35%	-$623K	﹤0.01%	339
2020 Q2	$1.89M	Buy	23,000 +4,000	+21%	+$308K	0.01%	306
2020 Q1	$1.12M	Buy	19,000 +3,000	+19%	+$244K	﹤0.01%	309
2019 Q4	$1.65M	Buy	16,000 +1,000	+7%	+$40.4K	0.01%	304
2019 Q3	$304K	Sell	15,000 -5,000	-25%	-$128K	﹤0.01%	390
2019 Q2	$515K	Buy	+20,000	New	+$401K	﹤0.01%	379

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fred Alger Management's AXSM Position: Q2 2025 in Review

Fred Alger Management sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 7,373 shares — an estimated $860K sold.

Fred Alger Management first reported a position in AXSM in Q2 2019 and held it in 10 quarters. The position peaked at $1.89M in Q2 2020. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

Fred Alger Management reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
Fred Alger Management sold 7,373 Axsome Therapeutics shares in Q2 2025, an estimated $860K.
Fred Alger Management first reported a position in Axsome Therapeutics in Q2 2019 and held it in 10 quarters.
Fred Alger Management's Axsome Therapeutics position peaked at $1.89M in Q2 2020.
348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Fred Alger Management's 13F filing for Q2 2025, filed 14 Aug 2025.